Your browser doesn't support javascript.
loading
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Thielmann, Carl M; Chorti, Eleftheria; Matull, Johanna; Murali, Rajmohan; Zaremba, Anne; Lodde, Georg; Jansen, Philipp; Richter, Luisa; Kretz, Julia; Möller, Inga; Sucker, Antje; Herbst, Rudolf; Terheyden, Patrick; Utikal, Jochen; Pföhler, Claudia; Ulrich, Jens; Kreuter, Alexander; Mohr, Peter; Gutzmer, Ralf; Meier, Friedegund; Dippel, Edgar; Weichenthal, Michael; Paschen, Annette; Livingstone, Elisabeth; Zimmer, Lisa; Schadendorf, Dirk; Hadaschik, Eva; Ugurel, Selma; Griewank, Klaus G.
Affiliation
  • Thielmann CM; Department of Dermatology, University Hospital Essen, University of Duisburg, Germany; German Cancer Consortium (DKTK), Partner Site Essen, Germany.
  • Chorti E; Department of Dermatology, University Hospital Essen, University of Duisburg, Germany; German Cancer Consortium (DKTK), Partner Site Essen, Germany.
  • Matull J; Department of Dermatology, University Hospital Essen, University of Duisburg, Germany; German Cancer Consortium (DKTK), Partner Site Essen, Germany.
  • Murali R; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Zaremba A; Department of Dermatology, University Hospital Essen, University of Duisburg, Germany; German Cancer Consortium (DKTK), Partner Site Essen, Germany.
  • Lodde G; Department of Dermatology, University Hospital Essen, University of Duisburg, Germany; German Cancer Consortium (DKTK), Partner Site Essen, Germany.
  • Jansen P; Department of Dermatology, University Hospital Essen, University of Duisburg, Germany; German Cancer Consortium (DKTK), Partner Site Essen, Germany.
  • Richter L; Department of Dermatology, University Hospital Essen, University of Duisburg, Germany; German Cancer Consortium (DKTK), Partner Site Essen, Germany.
  • Kretz J; Department of Dermatology, University Hospital Essen, University of Duisburg, Germany; German Cancer Consortium (DKTK), Partner Site Essen, Germany.
  • Möller I; Department of Dermatology, University Hospital Essen, University of Duisburg, Germany; German Cancer Consortium (DKTK), Partner Site Essen, Germany.
  • Sucker A; Department of Dermatology, University Hospital Essen, University of Duisburg, Germany; German Cancer Consortium (DKTK), Partner Site Essen, Germany.
  • Herbst R; Hauttumorzentrum, Helios Klinikum Erfurt, Erfurt, Germany.
  • Terheyden P; Department of Dermatology, UKSH Campus Lübeck, Lübeck, Germany.
  • Utikal J; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Heidelberg, Germany.
  • Pföhler C; Department of Dermatology, Saarland University Medical School, Homburg, Saar, Germany.
  • Ulrich J; Department of Dermatology and Venereology, Harzklinikum Dorothea Christiane Erxleben, Quedlinburg, Germany.
  • Kreuter A; Department of Dermatology, Venereology and Allergology, HELIOS St. Elisabeth Klinik Oberhausen, University Witten/Herdecke, Oberhausen, Germany.
  • Mohr P; Dermatological Center Buxtehude, Elbe Kliniken Buxtehude, Buxtehude, Germany.
  • Gutzmer R; Skin Cancer Center, Hannover Medical School, Hannover, Germany; Department of Dermatology, Mühlenkreiskliniken Minden, Minden, Germany.
  • Meier F; Department of Dermatology, Dermatooncology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
  • Dippel E; Department of Dermatology Ludwigshafen, Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Germany.
  • Weichenthal M; University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.
  • Paschen A; Department of Dermatology, University Hospital Essen, University of Duisburg, Germany; German Cancer Consortium (DKTK), Partner Site Essen, Germany.
  • Livingstone E; Department of Dermatology, University Hospital Essen, University of Duisburg, Germany; German Cancer Consortium (DKTK), Partner Site Essen, Germany.
  • Zimmer L; Department of Dermatology, University Hospital Essen, University of Duisburg, Germany; German Cancer Consortium (DKTK), Partner Site Essen, Germany.
  • Schadendorf D; Department of Dermatology, University Hospital Essen, University of Duisburg, Germany; German Cancer Consortium (DKTK), Partner Site Essen, Germany.
  • Hadaschik E; Department of Dermatology, University Hospital Essen, University of Duisburg, Germany; German Cancer Consortium (DKTK), Partner Site Essen, Germany.
  • Ugurel S; Department of Dermatology, University Hospital Essen, University of Duisburg, Germany; German Cancer Consortium (DKTK), Partner Site Essen, Germany.
  • Griewank KG; Department of Dermatology, University Hospital Essen, University of Duisburg, Germany; German Cancer Consortium (DKTK), Partner Site Essen, Germany. Electronic address: klaus.griewank@uk-essen.de.
Eur J Cancer ; 159: 113-124, 2021 12.
Article in En | MEDLINE | ID: mdl-34742158
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Neurofibromin 1 / Immune Checkpoint Inhibitors / Melanoma Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Eur J Cancer Year: 2021 Document type: Article Affiliation country: Germany Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Neurofibromin 1 / Immune Checkpoint Inhibitors / Melanoma Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Eur J Cancer Year: 2021 Document type: Article Affiliation country: Germany Country of publication: United kingdom